{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:24:41Z","timestamp":1783085081118,"version":"3.54.6"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.msard.2021.103480","type":"journal-article","created":{"date-parts":[[2022,1,2]],"date-time":"2022-01-02T17:21:45Z","timestamp":1641144105000},"page":"103480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS"],"prefix":"10.1016","volume":"58","author":[{"given":"Lana Zhovtis","family":"Ryerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Krupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh E.","family":"Charvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"de Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.msard.2021.103480_bib0001","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.103480_bib0002","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Adv. Neurol. Disord."},{"issue":"6","key":"10.1016\/j.msard.2021.103480_bib0003","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.msard.2021.103480_bib0004","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1007\/s10072-020-04838-z","article-title":"Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results","volume":"42","author":"Capra","year":"2020","journal-title":"Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2021.103480_bib0005","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2021.103480_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"15 Suppl","key":"10.1016\/j.msard.2021.103480_bib0007","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/WNL.94.15_supplement.1356","article-title":"Magnetic resonance imaging (MRI) metrics in routine clinical practice: proof of concept in MS PATHS (Multiple Sclerosis Partners Advancing Technology for Health Solutions)","volume":"94","author":"Fisher","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2021.103480_bib0008","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40263-018-0553-1","article-title":"Improvement in cognitive function as measured by NeuroTrax in patients with relapsing multiple sclerosis treated with natalizumab: a 2-year retrospective analysis","volume":"32","author":"Gudesblatt","year":"2018","journal-title":"CNS Drugs"},{"issue":"11","key":"10.1016\/j.msard.2021.103480_bib0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2021.103480_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102543","article-title":"Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study","volume":"46","author":"Horakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2021.103480_bib0011","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40263-015-0251-1","article-title":"Platform therapy compared with natalizumab for multiple sclerosis: relapse rates and time to relapse among propensity score-matched US patients","volume":"29","author":"Johnson","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2021.103480_bib0012","unstructured":"Kitzler, H.H., Jones, S., Blefari, M., Corredor-Jerez, R., Huelnhagen, T., Liao, S., et\u00a0al., 2020. In-clinic performance of MSPie, an image analysis prototype for automated MRI quantitative point-of-care metrics in MS. Presented at ECTRIMS virtual congress; 2020. P0592."},{"key":"10.1016\/j.msard.2021.103480_bib0013","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fneur.2020.00632","article-title":"Harnessing real-world data to inform decision-making: multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)","volume":"11","author":"Mowry","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103480_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of natalizumab treatment within 3\u2009years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC Neurol"},{"issue":"9","key":"10.1016\/j.msard.2021.103480_bib0015","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.103480_bib0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103480_bib0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1212\/CPJ.0000000000000227","article-title":"Comparative efficacy of first-line natalizumab vs IFN-\u03b2 or glatiramer acetate in relapsing MS","volume":"6","author":"Spelman","year":"2016","journal-title":"Neurol. Clin. Pract."},{"issue":"3","key":"10.1016\/j.msard.2021.103480_bib0018","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3174\/ajnr.A4539","article-title":"Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis","volume":"37","author":"Traboulsee","year":"2016","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2021.103480_bib0019","unstructured":"Tsang, A., Su, Y.-.C., Perea, R.D., Corredor-Jere, R., Fartaria, M.J., Huelnhagen, T., et\u00a0al., 2019. Brain volume measurements in multiple sclerosis patients: a novel combination approach for routine clinical assessment in MS paths. Presented at ISMRM; Montreal, Canada; May 11-16, 2019. P3159."},{"issue":"2","key":"10.1016\/j.msard.2021.103480_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrneurol.2017.171","article-title":"Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting","volume":"14","author":"Tur","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103480_bib0021","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2021.103480_bib0022","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/1352458520926869","article-title":"Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program","volume":"27","author":"Wiendl","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103480_bib0023","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.msard.2018.06.015","article-title":"Efficacy and safety of natalizumab extended interval dosing","volume":"24","author":"Yamout","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"15","key":"10.1016\/j.msard.2021.103480_bib0024","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2021.103480_bib0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100746X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482100746X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:03:35Z","timestamp":1761901415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482100746X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":25,"alternative-id":["S221103482100746X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103480","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103480"}}